home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 09/18/19

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2019 Results - Earnings Call Transcript

BeyondSpring Inc. (BYSI) Q2 2019 Earnings Conference Call September 18, 2019 08:00 ET Company Participants Stephen Kilmer - IR Lan Huang - Chairman & CEO Ramon Mohanlal - EVP of Research and Development and Chief Medical Officer Richard Daly - COO Edward Liu - CFO Conf...
BYSI - BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results

- To Submit New Drug Applications (“NDAs”) in China for Both Non-Small Cell Lung Cancer (“NSCLC”) and Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 - - To Submit NDAs in the United States (“U.S.”) for Both NSCLC and CIN in ...

BYSI - BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019

NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report second-quar...

BYSI - BeyondSpring's Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer

NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s novel design for Study 103 was selected for poster presentation at the I...
BYSI - BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate...

BYSI - BeyondSpring's Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the results of its head-to-head clinical trial for Study BPI-2358-105, accepted as an abstract titl...

BYSI - AVRO, NUS, SCPL and SGEN among midday movers

Gainers:  Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
BYSI - BeyondSpring prices stock offering at $17

BeyondSpring ( BYSI -11.6% ) has priced its public offering of 2,058,825 ordinary shares at $17.00 per share, for expected gross proceeds of $35M. More news on: BeyondSpring Inc., Healthcare stocks news, Read more ...

BYSI - BeyondSpring Announces Pricing of Public Offering of Ordinary Shares

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...

BYSI - BeyondSpring Announces Proposed Public Offering of Ordinary Shares

NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...
Previous 10 Next 10